Personalized health navigation company Transcarent is planning to purchase health benefits navigator Accolade for $621 million.
Transcarent plans to acquire Accolade for $7.03 per share in cash in the second quarter of 2025, according to a Jan. 8 news release.
The deal is being financed by General Catalyst and Glen Tullman's 62 Ventures. Upon completion, Accolade will become a privately held company and its common stock will no longer be listed on Nasdaq.
The transaction is expected to bring Transcarent's generative AI-powered WayFinding and comprehensive care experiences, including pharmacy benefits, together with Accolade's personalized healthcare platform and expertise in advocacy, expert medical opinions, and primary care.